CAS No. : 1405-41-0
|Size||Stock||Price||Quantity||Add to Cart||Quotation Online|
|Cat. No. :||CS-6360|
|CAS No. :||1405-41-0|
|M. Wt. :|
|Solubility:||H2O: ≥ 30 mg/mL|
Gentamicin sulfate, an aminoglycoside antibiotic, inhibits the growth of both gram-positive and gram-negative bacteria and to inhibit several strains of mycoplasma in tissue culture. It inhibits DNase I with an IC50 of 0.57 mM. IC50 & Target: IC50: 0.57 mM (DNase I) In Vitro: Gentamicin is a more effective in vitro bacterial inhibitor than combined penicillin-streptomycin, is nontoxic to tissue culture monolayers, and does not inhibit virus replication. It has been used with success as an additive in commercial mycology media to inhibit growth of bacteria and has been shown to be bactericidal for a wider range of organisms (Pseudomonas aeruginosa, Proteus sp., and Streptococcus faecalis) than penicillin and streptomycin. It does not interfere with the production of cytopathic effect by certain echoviruses and polioviruses in tissue culture, is nontoxic to Rhesus monkey kidney, HeLa, and human amnion cells, and is stable at autoclave temperatures. Gentamicin is produced by various species of the genus Micromonospora. Commercial gentamicin consists mainly of different gentamicin C components. Yoshizawa elucidates the 3D-structure of gentamicin C1a bound to an A-site RNA. Gentamicin C1a binds in the major groove of the A-site of the RNA. In Vivo: Gentamicin is currently the first choice aminoglycoside for the treatment of serious infections with alternatives being amikacin, netilmicin, and tobramycin. Gentamicin preparations are commercially available in three forms, namely otic, ophthalmic, and topical based on the respective function to treat infections of ear canal, eye, and skin. Oral and injectable forms of gentamicin are found to exhibit effective antibacterial activity against Yersinia pestis as demonstrated in a mouse infection model.Treatment with up to nine doses of methicillin or gentamicin shows a significant reduction of bacteria on the foreign body.
Protocol:Animal Administration: Mouse: Bacterial challenged mice are treated with methicillin, gentamicin, both methicillin and gentamicin, or no antibiotics. The treatment is given three times a day for up to 3 days. Each dose of methicillin is 75 mg per mouse (3 g/kg of body weight), and the gentamicin dose is 0.75 mg per mouse (0.03 g/kg). The antibiotics are given subcutaneously in 0.1 or 0.5 mL of saline. Mice are sacrificed and serum and aspirate samples are collected.
Rudin A, et al. Antibacterial activity of gentamicin sulfate in tissue culture. Appl Microbiol. 1970 Dec;20(6):989-90.
Xu W, et al. A rapid and sensitive method for kinetic study and activity assay of DNase I in vitro based on a GO-quenched hairpin probe. Anal Bioanal Chem. 2016 May;408(14):3801-9.
Kumar CG, et al. Microbial biosynthesis and applications of gentamicin: a critical appraisal.
Espersen F, et al. Effect of treatment with methicillin and gentamicin in a new experimental mouse model of foreignbody infection. Antimicrob Agents Chemother. 1994 Sep;38(9):2047-53.
- Select Batch :
- CS-6360 28647
- CS-6360 24092
|Tags:Gentamicin sulfate supplier,Gentamicin sulfate purchase,Gentamicin sulfate manufacturer,Gentamicin sulfate sigma,Gentamicin sulfate distributor,cost,Gentamicin sulfate buy,Gentamicin sulfate for sale|